STAT+: Dozens of institutional investors urge drugmakers to link executive compensation to access to medicines
Three dozen institutional investors are urging the boards at several of the world’s largest pharmaceutical companies to establish concrete metrics for linking executive compensation with policies that widen access to medicines to low- and middle-income countries.
In a series of letters, the investors asked the heads of board compensation committees to examine such steps as voluntary licensing agreements and technology transfer for generic production; supply chain performance for improving access to poor countries; transparency surrounding pricing policies; and access plans that focus specifically on diseases that affect people in these countries.
